LIFECORE BIOMEDICAL, INC. DE [LFCR] Filings

10-Q 1 lfcr-20230226.htm 10-Q lfcr-20230226

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Quarter Ended February 26, 2023, or


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition period for _________ to _________.

Commission file number: 000-27446

LIFECORE BIOMEDICAL, INC.

(Exact name of registrant as specified in its charter)


Delaware			94-3025618
(State or other jurisdiction of incorporation or organization)			(IRS Employer Identification Number)


3515 Lyman Boulevard
Chaska,	Minnesota	55318
(Address of principal executive offices)		(Zip Code)

(952) 368-4300

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, par value $0.001 per share	LFCR	The NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

☐

Accelerated Filer

☒

Emerging Growth Company

☐

Non Accelerated Filer

☐

Smaller Reporting Company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 26, 2023, there were 30,322,169 shares of common stock outstanding.

Table of Contents

LIFECORE BIOMEDICAL, INC.

FORM 10-Q

For the Fiscal Quarter Ended February 26, 2023

INDEX


			Page




Part I.	Financial Information

Item 1.	Financial Statements

	a)	Consolidated Balance Sheets as of February 26, 2023 and May 29, 2022	1

	b)	Consolidated Statements of Comprehensive (Loss) Income for the Three and Nine Months Ended February 26, 2023 and February 27, 2022	2

	c)	Consolidated Statement of Change in Convertible Preferred Stock and Stockholders’ Equity for the Three and Nine Months Ended February 26, 2023 and February 27, 2022	3

	d)	Consolidated Statements of Cash Flows for the Nine Months Ended February 26, 2023 and February 27, 2022	4

	e)	Notes to Consolidated Financial Statements	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		26

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		37

Item 4.	Controls and Procedures		37

Part II.	Other Information		39

Item 1.	Legal Proceedings		39

Item 1A.	Risk Factors		39

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		39

Item 3.	Defaults Upon Senior Securities		40

Item 4.	Mine Safety Disclosures		40

Item 5.	Other Information		40

Item 6.	Exhibits		40

	Signatures		42

Table of Contents

LIFECORE BIOMEDICAL, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except par value)


	February 26, 2023		May 29, 2022
	(unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	2,950	$	991
Accounts receivable, less allowance for credit losses	32,371		40,094
Inventories	48,696		44,300
Prepaid expenses and other current assets	4,422		5,183
Current assets, discontinued operations	—		33,144
Total Current Assets	88,439		123,712


Property and equipment, net	120,799		115,031
Operating lease right-of-use assets	5,924		6,519
Goodwill	13,881		13,881
Trademarks/tradenames, net	4,400		4,700

Other non-current assets	2,710		2,900
Non-current assets, discontinued operations	—		11,063
Total Assets	$	236,153	$	277,806

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	14,762	$	12,988
Accrued compensation	6,733		8,941
Other accrued liabilities	12,012		6,847
Current portion of lease liabilities	1,455		4,592
Deferred revenue	2,711		919
Line of credit	—		40,000
Current portion of long-term debt, net	—		98,178
Current liabilities, discontinued operations	—		4,345
Total Current Liabilities	37,673		176,810

Line of credit	16,000		—
Long-term debt, net	98,964		—
Long-term lease liabilities	10,516		8,356
Deferred taxes, net	80		126
Other non-current liabilities	203		190
Non-current liabilities, discontinued operations	—		1,627
Total Liabilities	163,436		187,109


Convertible Preferred Stock, 0.001 par value; 2,000 shares authorized; 39 shares issued and outstanding at February 26, 2023 (none at May 29, 2022), respectively	38,510		—

Stockholders’ Equity:
Common Stock, $0.001 par value; 50,000 shares authorized; 30,319 and 29,513 shares issued and outstanding at February 26, 2023 and May 29, 2022, respectively	30		30
Additional paid-in capital	174,268		167,352
Accumulated deficit	(140,091)		(76,099)
Accumulated other comprehensive loss	—		(586)
Total Stockholders’ Equity	34,207		90,697
Total Liabilities, Convertible Preferred Stock and Stockholders’ Equity	236,153		277,806

See accompanying notes to the consolidated financial statements.

-1-

Table of Contents

LIFECORE BIOMEDICAL, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(Unaudited)

(In thousands, except per share amounts)


	Three Months Ended				Nine Months Ended
	February 26, 2023		February 27, 2022		February 26, 2023		February 27, 2022
Product sales	$	27,600	$	37,399	$	77,748	$	90,140
Cost of product sales	21,622		24,533		58,178		58,507
Gross profit	5,978		12,866		19,570		31,633
Operating costs and expenses:
Research and development	1,964		2,000		6,128		5,722
Selling, general and administrative	10,972		14,163		31,201		27,659
Impairment of indefinite-lived intangible assets	—		—		300		—
Gain on sale of BreatheWay	—		—		(2,108)		—

Restructuring costs	2,741		5,270		4,611		7,530
Total operating costs and expenses	15,677		21,433		40,132		40,911
Operating loss	(9,699)		(8,567)		(20,562)		(9,278)

Interest income	22		20		53		66
Interest expense	(5,818)		(4,105)		(13,715)		(13,877)
Transition services income	70		5,473		70		5,473
Other income (expense), net	34		454		(481)		642
Net loss before tax	(15,391)		(6,725)		(34,635)		(16,974)
Income tax (expense) benefit	(70)		87		(78)		5,591
Net loss from continuing operations	(15,461)		(6,638)		(34,713)		(11,383)

Discontinued operations:
Loss from discontinued operations	$	(24,731)	$	(6,859)	$	(29,279)	$	(49,576)
Income tax (expense) benefit	—		411		—		(157)
Loss from discontinued operations, net of tax	(24,731)		(6,448)		(29,279)		(49,733)
Net loss	$	(40,192)	$	(13,086)	$	(63,992)	$	(61,116)

Basic net loss per share:
Loss from continuing operations	$	(0.51)	$	(0.23)	$	(1.16)	$	(0.39)
Loss from discontinued operations	(0.82)		(0.22)		(0.98)		(1.68)
Total basic net loss per share	$	(1.33)	$	(0.45)	$	(2.14)	$	(2.07)

Diluted net loss per share:
Loss from continuing operations	$	(0.51)	$	(0.23)	$	(1.16)	$	(0.39)
Loss from discontinued operations	(0.82)		(0.22)		(0.98)		(1.68)
Total diluted net loss per share	$	(1.33)	$	(0.45)	$	(2.14)	$	(2.07)

Shares used in per share computation:
Basic	30,304		29,482		29,838		29,459
Diluted	30,304		29,482		29,838		29,459

Other comprehensive income, net of tax:
Net unrealized gain on interest rate swaps (net of tax effect of $0, $(100), $(16) and $(190))	$	—	$	104	$	586	$	646
Other comprehensive income, net of tax	—		104		586		646
Total comprehensive loss	$	(40,192)	$	(12,982)	$	(63,406)	$	(60,470)

See accompanying notes to the consolidated financial statements.

-2-

Table of Contents

LIFECORE BIOMEDICAL, INC.

CONSOLIDATED STATEMENT OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY

(Unaudited) (In thousands)


Three and Nine Months Ended February 26, 2023
	Convertible Preferred Stock			Common Stock			Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders’ Equity

	Shares	Amount		Shares	Amount
Balance at May 29, 2022	—	$	—	29,513	$	30	$	167,352	$	(76,099)	$	(586)	$	90,697
Issuance of stock under stock plans, net of shares withheld	—	—		80	—		—		—		—		—
Taxes paid by Company for employee stock plans	—	—		—	—		(67)		—		—		(67)
Stock-based compensation	—	—		—	—		785		—		—		785
Net loss	—	—		—	—		—		(11,351)		—		(11,351)
Other comprehensive income, net of tax	—	—		—	—		—		—		300		300
Balance at August 28, 2022	—	$	—	29,593	$	30	$	168,070	$	(87,450)	$	(286)	$	80,364
Issuance of stock under stock plans, net of shares withheld	—	—		76									—
Taxes paid by Company for employee stock plans	—	—		—	—		(142)		—				(142)
Stock-based compensation	—	—		—	—		1,108		—				1,108
Net loss	—	—		—	—		—		(12,449)				(12,449)
Other comprehensive income, net of tax	—	—		—	—		—		—		286		286
Issuance of shares to Wynnefield Capital, Inc.	—	—		628	—		5,000		—		—		5,000
Balance at November 27, 2022	—	$	—	30,297	$	30	$	174,036	$	(99,899)	$	—	$	74,167
Issuance of stock under stock plans, net of shares withheld				22	—		—		—		—		—
Proceeds of Convertible Preferred Stock, net of issuance costs	39	38,082		—	—		—		—		—		—
Convertible Preferred Stock PIK dividend	—	428		—	—		(428)		—		—		(428)
Cost of issuance of shares to Wynnefield Capital, Inc.	—	—		—	—		(178)		—		—		(178)
Taxes paid by Company for employee stock plans	—	—		—	—		(65)		—		—		(65)
Stock-based compensation	—	—		—	—		903		—		—		903
Net loss	—	—		—	—		—		(40,192)		—		(40,192)

Balance at February 26, 2023	39	$	38,510	30,319	$	30	$	174,268	$	(140,091)	$	—	$	34,207


Three and Nine Months Ended February 27, 2022
							Additional Paid-in Capital		Retained Earnings (Accumulated Deficit)		Accumulated Other Comprehensive Loss		Total Stockholders’ Equity
	Convertible Preferred Stock			Common Stock
	Shares	Amount		Shares	Amount

Balance at May 30, 2021	—	—		29,333	29		165,533		38,580		(1,358)		202,784
Issuance of stock under stock plans, net of shares withheld	—	—		129	—		—		—		—		—
Taxes paid by Company for employee stock plans	—	—		—	—		(428)		—		—		(428)
Stock-based compensation	—	—		—	—		620		—		—		620
Net loss	—	—		—	—		—		(9,509)		—		(9,509)
Other comprehensive income, net of tax	—	—		—	—		—		—		366		366
Balance at August 29, 2021	—	$	—	29,462	$	29	$	165,725	$	29,071	$	(992)	$	193,833
Issuance of stock under stock plans, net of shares withheld	—	—		19	—		—		—		—		—
Taxes paid by Company for employee stock plans	—	—		—	—		(84)		—		—		(84)
Stock-based compensation	—	—		—	—		686		—		—		686
Net loss	—	—		—	—		—		(38,521)		—		(38,521)
Other comprehensive income, net of tax	—	—		—	—		—		—		176		176
Balance at November 28, 2021	—	$	—	29,481	$	29	$	166,327	$	(9,450)	$	(816)	$	156,090
Issuance of stock under stock plans, net of shares withheld	—	—		1	—		—		—		—		—
Taxes paid by Company for employee stock plans	—	—		—	—		(6)		—		—		(6)
Stock-based compensation	—	—		—	—		622		—		—		622
Net loss	—	—		—	—		—		(13,086)		—		(13,086)
Other comprehensive income, net of tax	—	—		—	—		—		—		104		104
Balance at February 27, 2022	—	$	—	29,482	$	29	$	166,943	$	(22,536)	$	(712)	$	143,724

See accompanying notes to the consolidated financial statements.

-3-

Table of Contents

LIFECORE BIOMEDICAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited) (In thousands)


	Nine Months Ended
	February 26, 2023		February 27, 2022
Cash flows from operating activities:
Net loss	$	(63,992)	$	(61,116)
Adjustments to reconcile net loss to net cash used in operating activities:
Impairment of indefinite-lived intangible assets and goodwill	300		32,057
Depreciation, amortization of intangibles, debt costs and right-of-use assets	10,392		14,488
Gain on sale of BreatheWay	(2,108)		—
Stock-based compensation expense	2,796		1,928
Deferred taxes	57		(5,471)
Loss on disposal of property and equipment related to restructuring, net	—		5,185


Loss on sale of Yucatan	21,039		—
Loss on sale of Eat Smart	—		235


Other, net	101		(540)
Changes in current assets and current liabilities:
Accounts receivable, net	8,994		(7,525)
Inventories	(13,451)		(11,910)
Prepaid expenses and other current assets	(1,169)		(1,448)
Accounts payable	11,405		13,507
Accrued compensation	(1,895)		(2,027)
Other accrued liabilities	8,570		(70)
Deferred revenue	1,792		662
Net cash used in operating activities	(17,169)		(22,045)

Cash flows from investing activities:
Purchases of property and equipment	(12,319)		(18,539)
Proceeds from the sale of BreatheWay, net	3,135		—
Proceeds from the sale of Yucatan, net	12,531		—
Proceeds from the sale of Eat Smart, net	—		73,500
Eat Smart sale net working capital adjustments	—		(2,390)
Sale of Investment in non-public company	—		45,100

Proceeds from sales of property and equipment	—		1,096
Net cash provided by investing activities	3,347		98,767

Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	4,822		—
Proceeds from long-term debt	3,367		—
Payments on long-term debt	(3,199)		(86,376)
Proceeds from lines of credit	18,400		45,011
Payments on lines of credit	(42,400)		(34,111)
Taxes paid for employee stock plans	(274)		(518)
Payments for debt issuance costs	(3,669)		(169)
Proceeds from sale of preferred stock, net of issuance costs	38,082		—
Net cash provided by (used in) financing activities	15,129		(76,163)
Net increase in cash and cash equivalents	1,307		559
Cash and cash equivalents, beginning of period	1,643		1,295
Cash and cash equivalents, end of period	$	2,950	$	1,854

Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment on trade vendor credit	$	3,918	$	1,764
Convertible Preferred Stock PIK dividend	$	(428)	$	—

See accompanying notes to the consolidated financial statements.

-4-

Table of Contents

LIFECORE BIOMEDICAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization, Basis of Presentation, and Summary of Significant Accounting Policies

Organization

Lifecore Biomedical, Inc. and its subsidiaries (“Lifecore Biomedical” or the “Company”, previously Landec Corporation) design, develop, manufacture, and sell differentiated products for food and biomaterials markets, and license technology applications to partners.

Lifecore Biomedical’s biomedical company, Lifecore Biomedical Operating Company, Inc. (“Lifecore”), is a fully integrated contract development and manufacturing organization (“CDMO”) that offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings 37 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. Lifecore recognizes revenue in two different product categories, CDMO and Fermentation.

Lifecore Biomedical previously operated a natural food company, through its wholly owned subsidiary, Curation Foods, Inc. (“Curation Foods”), which was previously focused on the distribution of plant-based foods to retail, club and foodservice channels throughout North America, which was presented in Lifecore Biomedical’s prior financial statements as the Curation Foods segment. However, upon the sale of Yucatan Foods on February 7, 2023 (see “Yucatan Disposition and Discontinued Operations” below) and O Olive Oil & Vinegar (“O Olive”) on April 6, 2023, (refer to Note 10), the Company has ceased to operate the Curation Foods business. Accordingly, commencing in the fourth quarter of fiscal year 2023, the Curation Foods segment of Lifecore Biomedical will be presented as a discontinued operation in its entirety.

On November 14, 2022, the Company filed an amendment to the Certificate of Incorporation to change the Company’s name from Landec Corporation to Lifecore Biomedical, Inc. (the “Name Change”), which was approved by the board of directors of the Company and became effective on November 14, 2022. In connection with the Name Change, the Company’s common stock began trading under its new NASDAQ ticker symbol, “LFCR”, on November 15, 2022. References to “Landec” or “Landec Corporation” refer to operations and/or transactions of the Company prior to the Name Change.

Yucatan Disposition and Discontinued Operations

On February 7, 2023 (the “Closing Date”), Company, Camden Fruit Corp., a direct wholly owned subsidiary of Curation Foods and an indirect wholly owned subsidiary of the Company (“Camden” and together with the Curation Foods and the Company, the “Sellers”), Yucatan Foods, LLC, a wholly owned subsidiary of the Camden (“Yucatan”), and Yucatan Acquisition Holdings LLC, a wholly owned subsidiary of Flagship Food Group LLC (“Buyer” and together with Yucatan and the Sellers, the “Parties”) completed the sale (the “Yucatan Disposition”) of the Company’s avocado products business, including its Yucatan® and Cabo Fresh® brands, as well as the associated manufacturing facility and operations in Guanajuato, Mexico (the “Business”), pursuant to the terms of a securities purchase agreement executed by the Parties on February 7, 2023 (the “Securities Purchase Agreement”). Pursuant to the Securities Purchase Agreement, Buyer acquired all of the outstanding equity securities of Yucatan for a purchase price of $17.5 million in cash, subject to certain post-closing adjustments at closing, including selling costs, net working capital and other adjustments amounting to $5.0 million. The Company recognized a loss on the Yucatan Disposition of $21.0 million in the third quarter ended February 26, 2023. The loss on the Yucatan Disposition is recorded in loss from discontinued operations in the Consolidated Statement of Comprehensive (Loss) Income.

The accounting requirements for reporting the Yucatan Foods business as discontinued operations were met when the Yucatan Disposition was completed on the Closing Date. Accordingly, the consolidated financial statements and notes to the consolidated financial statements reflect the results of the Yucatan business as a discontinued operation for the periods presented. Refer to Note 9 - Discontinued Operations for additional information.

Securities Purchase Agreement

-5-

Table of Contents

On November 25, 2022, the Company entered into a Securities Purchase Agreement (the “Wynnefield Purchase Agreement”) with entities affiliated with Wynnefield Capital, Inc. (the “Purchasers”). Pursuant to the Wynnefield Purchase Agreement, the Company agreed to sell an aggregate of 627,746 shares of its common stock (the “Shares”) for aggregate gross proceeds of approximately $5.0 million (the “Offering”). The purchase price for each Share was $7.97. The Offering closed on November 25, 2022. Pursuant to the Wynnefield Purchase Agreement, the Company granted the Purchasers certain piggyback registration rights and agreed, among other things, to indemnify such parties under any registration statement filed that includes the Shares from certain losses, claims, damages and liabilities.

Series A Convertible Preferred Share Purchase Agreement

On January 9, 2023, the Company simultaneously signed and closed a Securities Purchase Agreement (the “Preferred Share Purchase Agreement”) with a group of certain accredited investors. Refer to Note 2 – Convertible Preferred Stock for additional information.

Amendment to Credit Agreements

On January 9, 2023, the Company entered into certain amendments to its existing Credit Facilities (defined below). Refer to Note 6 – Debt and Note 10 – Subsequent Events for additional information.

Basis of Presentation

The accompanying unaudited consolidated financial statements of Lifecore Biomedical have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial information and with the instructions for Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring accruals) have been made which are necessary to present fairly the financial position of the Company at February 26, 2023, and the results of operations and cash flows for all periods presented. Although Lifecore Biomedical believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements and related footnotes prepared in accordance with GAAP have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying financial data should be reviewed in conjunction with the audited financial statements and accompanying notes included in Lifecore Biomedical’s Annual Report on Form 10-K/A for the fiscal year ended May 29, 2022 (the “Annual Report”).

The Company’s fiscal year is the 52- or 53-week period that ends on the last Sunday of May with quarters within each year ending on the last Sunday of August, November, and February; however, in instances where the last Sunday would result in a quarter being 12-weeks in length, the Company’s policy is to extend that quarter to the following Sunday. A 14th week is included in the fiscal year every five or six years to realign the Company’s fiscal quarters with calendar quarters.

The results of operations for the three and nine months ended February 26, 2023 are not necessarily indicative of the results that may be expected for an entire fiscal year because there is some seasonality in the order patterns of Lifecore’s customers which may lead to significant fluctuations in Lifecore Biomedical’s quarterly results of operations.

Basis of Consolidation

The consolidated financial statements are presented on the accrual basis of accounting in accordance with GAAP and include the accounts of Lifecore Biomedical and its subsidiaries, Lifecore and Curation Foods. All material inter-company transactions and balances have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make certain estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates that require management’s most significant and subjective judgments include revenue recognition; loss contingencies; sales returns and credit losses; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived and indefinite lived assets (including intangible assets and goodwill), and inventory; and the valuation and recognition of stock-based compensation.

These estimates involve the consideration of complex factors and require management to make judgments. The analysis of historical and future trends can require extended periods of time to resolve and are subject to change from period to period. The actual results may differ from management’s estimates.

-6-

Table of Contents

Going Concern Update

As disclosed in the Company’s previous filings, the Company had previously determined that there were factors, which was principally the result of our noncompliance with financial covenants, that raised substantial doubt about its ability to continue as a going concern. Since that time, the Company has taken measures to strengthen its financial position, including the repayment and termination of the Prior Term Loan Facility, and the entry into the Refinancing Transactions (defined below), in each case, on May 22, 2023. The Refinancing Transactions provided the Company with additional liquidity, eliminated the Company’s noncompliance with its financial covenants under Credit Facilities (including granting the Company applicable waivers under the Revolving Term Loan Facility), reduced the Company’s near-term debt service costs, and eliminated certain financial covenants that existed under the Prior Term Loan Facility. In addition, the completion of the Company’s sale of the Yucatan and O Olive business, and the entry into an amended and restated supply agreement with Alcon Research, LLC (“Alcon”) to extend and expand its prior supply agreement, as further described in Note 10 – Subsequent Events, also provided the Company with additional liquidity. The cash provided under the Refinancing Transactions, completed divestitures of remaining Curation Foods businesses, and the lower debt service costs under our Refinancing Transactions provide improved forecasted cash flow from operations that allow sufficient liquidity over the next 12 months to meet our obligations as they come due.

Based on the foregoing, management believes that our cash position as of the date of filing these financial statement (the “Filing Date”) and forecasted cash flow from operations is sufficient to meet capital and liquidity requirements for at least the next 12 months. As a result, there is no longer substantial doubt about the Company’s ability to continue as a going concern.

Cash and Cash Equivalents

The Company records all highly liquid securities with three months or less from date of purchase to maturity as cash equivalents. Cash equivalents consist mainly of money market funds. The market value of cash equivalents approximates their historical cost given their short-term nature.

Reconciliation of Cash and Cash Equivalents as presented on the Statements of Cash Flows

The following table provides a reconciliation of cash and cash equivalents and cash and cash equivalents, discontinued operations within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows:


(In thousands)	February 26, 2023		May 29, 2022		February 27, 2022		May 30, 2021
Cash and cash equivalents	$	2,950	$	991	$	1,854	$	1,159
Cash and cash equivalents, discontinued operations	—		652		—		136


Cash and cash equivalents	$	2,950	$	1,643	$	1,854	$	1,295

Inventories

Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value and consist of the following:


(In thousands)	February 26, 2023		May 29, 2022
Finished goods	$	14,636	$	13,418
Raw materials	22,554		21,329
Work in progress	11,506		9,553
Total	$	48,696	$	44,300

If the cost of the inventories exceeds their net realizable value, provisions are recorded currently to reduce them to net realizable value. The Company also records a provision for slow moving and obsolete inventories based on the estimate of demand for its products.

-7-

Table of Contents

Accounts Receivable, Sales Returns and Allowance for Credit Losses

The Company carries its accounts receivable at their face amounts less an allowance for estimated sales returns and credit losses. Sales return allowances are estimated based on historical sales return amounts.

The Company uses the loss rate method to estimate its expected credit losses on trade accounts receivable and contract assets. In order to estimate expected credit losses, the Company assessed recent historical experience, current economic conditions and any reasonable and supportable forecasts to identify risk characteristics that are shared within the financial asset. These risk characteristics are then used to bifurcate the loss rate method into risk pools. The risk pools were determined based on the industries in which the Company operates. Historical credit loss for each risk pool is then applied to the current period aging as presented in the identified risk pools to determine the needed reserve allowance. At times when there are no current economic conditions or forecasts that may affect future credit losses, the Company has determined that recent historical experience provides the best basis for estimating credit losses.

The information obtained from assessing historical experience, current economic conditions and reasonable and supportable forecasts were used to identify risk characteristics that can affect future credit loss experience. There were no significant risk characteristics identified in the review of historical experiences or in the review of estimates of current economic conditions and forecasts.

Estimating credit losses based on risk characteristics requires significant judgment by management. Significant judgments include, but are not limited to: assessing current economic conditions and the extent to which they are relevant to the existing characteristics of the Company’s financial assets, the estimated life of financial assets, and the level of reliance on historical experience in light of economic conditions. The Company will continually review and update, when necessary, its historical risk characteristics that are meaningful to estimating credit losses, any new risk characteristics that arise in the natural course of business, and the estimated life of its financial assets.

The changes in the Company’s allowance for credit losses are summarized in the following table (in thousands):


	Balance at beginning of period		Provision (benefit) for expected credit losses		Write offs, net of recoveries		Balance at end of period
Nine months ended February 26, 2023	$	5	$	—	$	(1)	$	4
Nine months ended February 27, 2022	$	5	$	—	$	—	$	5

Debt Issuance Costs

The Company records its line of credit debt issuance costs as an asset, and as such, $0.7 million and $1.3 million were recorded as Prepaid expenses and other current assets, and Other non-current assets in the accompanying Consolidated Balance Sheets, respectively, as of February 26, 2023, and $0.7 million and $1.9 million, respectively, as of May 29, 2022. The Company records its term debt issuance costs as a contra-liability, and as such, $8.1 million and $5.5 million were recorded as a reduction to long-term debt, net and current portion of long-term debt, net in the accompanying Consolidated Balance Sheets, respectively, as of February 26, 2023 and May 29, 2022.

Financial Instruments

The Company’s financial instruments are primarily composed of commercial-term trade payables, debt instruments, and derivative instruments. For short-term instruments, the historical carrying amount approximates the fair value of the instrument. The fair value of long-term debt and lines of credit approximates their carrying value.

Cash Flow Hedges

The Company has entered into interest rate swap agreements to manage interest rate risk. These derivative instruments may offset a portion of the changes in interest expense. The Company designates these derivative instruments as cash flow hedges. The Company accounts for its derivative instruments as either an asset or a liability and carries them at fair value in Other assets or Other non-current liabilities. The accounting for changes in the fair value of the derivative instrument depends on the intended use of the derivative instrument and the resulting designation.

-8-

Table of Contents

For derivative instruments that hedge the exposure to variability in expected future cash flows and are designated as cash flow hedges, the entire change in the fair value of the hedging instrument is recorded as a component of Accumulated other comprehensive loss (“AOCL”) in Stockholders’ Equity. Those amounts are subsequently reclassified to earnings in the same line item in the Consolidated Statements of Comprehensive (Loss) Income as impacted when the hedged item affects earnings. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions.

During the third quarter of fiscal year 2021, the Company discontinued its hedge accounting prospectively since it was determined that the derivatives are no longer highly effective in offsetting changes in the net investment. The derivatives continue to be carried at fair value in the accompanying Consolidated Balance Sheets with changes in their fair values from the date of discontinued hedge accounting recognized in current period earnings in Other income (expense), net in the Consolidated Statements of Comprehensive (Loss) Income. Amounts previously accumulated in AOCL during the period of effectiveness will continue to be realized over the remaining term of the underlying forecasted debt payments as a component of AOCL in Stockholders’ Equity.

Accumulated Other Comprehensive Loss

Comprehensive income (loss) consists of two components, net loss and other comprehensive income (loss) (“OCI”). OCI refers to revenue, expenses, and gains and losses that under GAAP are recorded as a component of stockholders’ equity but are excluded from net loss. The Company’s OCI consists of net deferred gains and losses on its interest rate swap derivative instruments. The components of AOCL, net of tax, are as follows:


(In thousands)	AOCL
Balance as of May 29, 2022	$	(586)

Amounts reclassified from OCI	586
Other comprehensive income, net	$	586
Balance as of February 26, 2023	$	—

Assets Held for Sale

In May 2021, the Board of Directors approved a plan to sell Curation Foods’ Rock Hill, South Carolina distribution facility. There was no impairment recorded in fiscal year 2021. The asset was sold on June 9, 2021 for gross proceeds of $1.1 million. A gain of $0.6 million was recorded upon the sale and was included in loss from discontinued operations within the Consolidated Statements of Comprehensive (Loss) Income.

In May 2022, the Board of Directors approved a plan to sell the assets of Curation Foods’ BreatheWay packaging technology business. The $1.0 million carrying value of these assets ($0.9 million of inventory and $0.1 million net book value of property and equipment) are included in Prepaid expenses and other current assets on the Consolidated Balance Sheets as of May 29, 2022 and were classified as assets held for sale. These assets were sold during the first quarter of fiscal year 2023 for net proceeds of $3.1 million. A gain of $2.1 million was recorded upon the sale, which is included in Selling, general and administrative within the Consolidated Statements of Comprehensive (Loss) Income for the nine months ended February 26, 2023.

Leases

Under Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate is a quoted rate based on the understanding of what the Company’s credit rating would be. Certain agreements may contain the option to extend the lease term, terminate the lease before the contractual expiration date, or purchase the leased asset. The Company, when reasonably certain to exercise the option, considers these options in determining the measurement of the lease. The Company’s lease agreements do not contain any material residual value guarantees.

The Company’s lease agreements generally contain lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. The Company combines fixed payments for non-lease components with lease payments and accounts for them together as a single lease component which increases the amount of lease assets and liabilities.

-9-

Table of Contents

Payments under lease arrangements are primarily fixed; however, certain lease agreements contain variable payments, which are expensed as incurred and are not included in the operating lease assets and liabilities. These amounts primarily include payments affected by changes in price indices.

Long-lived and Indefinite-Lived Intangible Assets

The Company’s intangible assets are comprised of customer relationships with a finite estimated useful life of 12 years, and trademarks/tradenames and goodwill with indefinite useful lives.

During the nine months ended February 26, 2023, the Company recorded an impairment charge of $1.0 million related to Yucatan Foods indefinite-lived intangible asset related to trademarks/tradenames which is included in discontinued operations. In addition, during the nine months ended February 26, 2023, the Company recorded an impairment charge of $0.3 million related to O Olive’s indefinite-lived intangible asset for their trademarks/tradenames. The impairments were determined using the royalty savings method to estimate the fair value of its trademarks and was primarily a result of an indication of a decrease in the fair market value of the Yucatan Foods and O Olive businesses driven by lower market valuations and a decrease in projected cash flows. The O Olive impairment charge is included in the line item “Impairment of indefinite-lived intangible assets” on the Consolidated Statements of Comprehensive (Loss) Income, and is reported in the Curation Foods business segment (See Note 7).

Fair Value Measurements

The Company uses fair value measurement accounting for financial assets and liabilities and for financial instruments and certain other items measured at fair value. The Company has elected the fair value option for its investment in a non-public company. The Company has not elected the fair value option for any of its other eligible financial assets or liabilities.

The accounting guidance established a three-tier hierarchy for fair value measurements, which prioritizes the inputs used in measuring fair value as follows:

Level 1 – observable inputs such as quoted prices for identical instruments in active markets.

Level 2 – inputs other than quoted prices in active markets that are observable either directly or indirectly through corroboration with observable market data.

Level 3 – unobservable inputs in which there is little or no market data, which would require the Company to develop its own assumptions.

As of February 26, 2023 and May 29, 2022, the Company held certain assets and liabilities that are required or it elected to be measured at fair value on a recurring basis, including its interest rate swap contracts.

As of May 29, 2022, related to the assets of Curation Foods’ BreatheWay packaging technology business, the Company had $1.0 million in Prepaid expenses and other current assets within the Consolidated Balance Sheet meeting the criteria of held for sale. These assets are recognized at the lower of cost or fair value less cost to sell using market approach. The fair value of these assets are classified as level 3 in the fair value hierarchy due to a mix of unobservable inputs utilized such as independent research in the market as well as actual quotes from market participants.

Imprecision in estimating unobservable market inputs can affect the amount of gain or loss recorded for a particular position. The use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

-10-

Table of Contents

The following table summarizes the fair value of the Company’s assets and liabilities that are measured at fair value on a recurring and nonrecurring basis (in thousands):


	Fair Value at February 26, 2023						Fair Value at May 29, 2022
Assets:	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Assets held for sale - nonrecurring	$	—	$	—	$	—	$	—	$	—	$	1,027
Current assets, discontinued operation
Property & equipment	—		—		—		—		3,500		—
Customer relationship	—		—		—		—		—		1,400
Tradenames	—		—		—		—		—		4,000
Total assets	—		—		—		—		3,500		6,427

Revenue Recognition

The Company follows the five step, principles-based model to recognize revenue upon the transfer of promised goods or services to customers and in an amount that reflects the consideration for which the Company expects to be entitled in exchange for those goods or services. Revenue, net of estimated allowances and returns, is recognized when or as the Company satisfies its performance obligations under a contract and control of the product is transferred to the customer.

Lifecore

Lifecore generates revenue from two integrated activities: CDMO and Fermentation. CDMO is comprised of aseptic and development services. Lifecore’s standard terms of sale are generally included in its contracts and purchase orders. Shipping and other transportation costs charged to customers are recorded in both revenue and cost of goods sold. Lifecore has elected to account for shipping and handling as fulfillment activities, and not as a separate performance obligation. Lifecore’s standard payment terms with its customers generally range from 30 days to 60 days.

Aseptic

Lifecore provides aseptic formulation and filling of syringes and vials with precisely formulated medical grade HA and non-HA materials for injectable products used for medical purposes. In instances where our customers contract with us to aseptically fill syringes or vials with our HA, the goods are not distinct in the context of the contract. Lifecore recognizes revenue for these products at the point in time when legal title to the product is transferred to the customer, which is at the time that shipment is made or upon delivery of the product.

Development Services

Lifecore provides product development services to assist its customers in obtaining regulatory approval for the commercial sale of their drug product. These services include activities such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation and production of materials for use within clinical studies. The Company’s customers benefit from the expertise of its scientists who have extensive experience performing such tasks.

Each of the promised goods and services are not distinct in the context of the contract as the goods and services are highly interdependent and interrelated. The services described above are significantly affected by each other because Lifecore would not be able to fulfill its promise by transferring each of the goods or services independently.

Revenues generated from development services arrangements are recognized over time as Lifecore is creating an asset without an alternate use as it is unique to the customer. Furthermore, the Company has an enforceable right to payment for the performance completed to date for its costs incurred in satisfying the performance obligation plus a reasonable profit margin. For each of the development activities performed by Lifecore as described above, labor is the primary input (i.e., labor costs represent the majority of the costs incurred in the completion of the services). The Company determined that labor hours are the best measure of progress as it most accurately depicts the effort extended to satisfy the performance obligation over time.

Fermentation

-11-

Table of Contents

Lifecore manufactures and sells pharmaceutical-grade sodium hyaluronate (“HA”) in bulk form to its customers. The HA produced is distinct as customers are able to utilize the product provided under HA supply contracts when they obtain control. Lifecore recognizes revenue for these products at the point in time when legal title to the product is transferred to the customer, which is at the time that shipment is made or upon delivery of the product to our customer.

Curation Foods

Curation Foods’ standard terms of sale, both prior to and following the Eat Smart Disposition and Yucatan Disposition, are generally included in its contracts and purchase orders. Revenue is recognized at the time shipment is made or upon delivery as control of the product is transferred to the customer. Shipping and other transportation costs charged to customers are recorded in both revenue and cost of goods sold. Curation Foods has elected to account for shipping and handling as fulfillment activities, and not as a separate performance obligation. Curation Foods’ standard payment terms with its customers generally range from 30 days to 90 days. Certain customers may receive cash-based incentives (including: volume rebates, discounts, and promotions), which are accounted for as variable consideration to Curation Foods’ performance obligations. Curation Foods estimates these sales incentives based on the expected amount to be provided to its customers and reduces revenues recognized towards its performance obligations. The Company has not historically had and does not anticipate significant changes in its estimates for variable consideration.

The Company disaggregates its revenue by segment based on how it markets its products and services and reviews results of operations. The following tables disaggregate segment revenue by major product lines and services:


(In thousands)	Three Months Ended				Nine Months Ended
Lifecore:	February 26, 2023		February 27, 2022		February 26, 2023		February 27, 2022
Contact development and manufacturing organization	$	17,809	$	24,799	$	52,088	$	63,951
Fermentation	8,521		10,009		19,635		17,756

Total	$	26,330	$	34,808	$	71,723	$	81,707


(In thousands)	Three Months Ended				Nine Months Ended
Curation Foods:	February 26, 2023		February 27, 2022		February 26, 2023		February 27, 2022
Olive Oil and vinegars	$	1,270	$	2,169	$	6,025	$	7,016
Technology	—		422		—		1,417
Total	$	1,270	$	2,591	$	6,025	$	8,433

Contract Assets and Liabilities

Contract assets primarily relate to the Company’s conditional right to consideration for work completed but not billed at the reporting date. The Company’s contract assets as of February 26, 2023 and May 29, 2022, were $4.7 million and $10.2 million, respectively.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company’s contract liabilities as of February 26, 2023 and May 29, 2022, were $2.7 million and $0.9 million, respectively. Revenue recognized during the three and nine months ended February 26, 2023, that was included in the contract liability balance at the beginning of fiscal year 2023, was $0.1 million and $0.5 million, respectively.

Shipping and Handling Costs

Amounts billed to third-party customers for shipping and handling are included as a component of revenues. Shipping and handling costs incurred are included as a component of cost of products sold and represent costs incurred to ship product from the processing facility or distribution center to the end consumer markets.

Legal Contingencies

In the ordinary course of business, the Company is involved in various legal proceedings and claims.

-12-

Table of Contents

The Company makes a provision for a liability relating to legal matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These provisions are reviewed at least each fiscal quarter and adjusted to reflect the impacts of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. Legal fees are expensed in the period in which they are incurred.

Compliance Matters and Related Litigation

On December 1, 2018, the Company acquired all of the voting interests and substantially all of the assets of Yucatan Foods (the “Yucatan Acquisition”), which owns a guacamole manufacturing plant in Mexico called Procesadora Tanok, S de RL de C.V. (“Tanok”).

On October 21, 2019, the Company retained Latham & Watkins LLP to conduct an internal investigation relating to potential environmental and Foreign Corrupt Practices Act (“FCPA”) compliance matters associated with regulatory permitting at the Tanok facility in Mexico. The Company subsequently disclosed to the U.S. Securities and Exchange Commission (“SEC”) and the U.S. Department of Justice (“DOJ”) the conduct under investigation, and these agencies have commenced an investigation. The Company has also disclosed the conduct under investigation to the Mexican Attorney General’s Office, which has commenced an investigation, and to Mexican regulatory agencies. The Company is cooperating in the government investigations and requests for information. The conduct at issue began prior to the Yucatan Acquisition, and the agreement for the Yucatan Acquisition provides the Company with certain indemnification rights that may allow the Company to recover the cost of a portion of the liabilities that have been and may be incurred by the Company in connection with these compliance matters. On September 2, 2020, one of the former owners of Yucatan filed a lawsuit against the Company in Los Angeles County Superior Court for breach of employment agreement, breach of contract, breach of holdback agreement, declaratory relief and accounting, and related claims. The Plaintiff seeks over $10 million in damages, including delivery of shares of his stock held in escrow for the indemnification claims described above. On November 3, 2020, the Company filed an answer and cross-complaint against the Plaintiff and other parties for fraud, indemnification, and other claims, and seeking no less than $80 million in damages.

At this stage, the u

LIFECORE BIOMEDICAL, INC. DE [LFCR] Filings
10-Q	[2023-06-02]
S-1	[2023-04-06]
10-Q	[2023-03-16]
10-Q	[2022-10-07]
10-K	[2022-09-14]
10-Q	[2022-04-07]
10-Q	[2022-01-07]
10-Q	[2021-10-05]
10-K	[2021-07-29]
10-Q	[2021-04-08]
10-Q	[2021-01-07]
10-Q	[2020-10-07]
10-K	[2020-08-14]
10-Q	[2020-04-03]
10-Q	[2020-01-02]
10-Q	[2019-10-03]
10-K	[2019-08-01]
10-Q	[2019-04-04]
10-Q	[2019-01-07]
10-Q	[2018-10-05]
10-K	[2018-08-09]
10-Q	[2018-04-05]
10-Q	[2018-01-05]
10-Q	[2017-09-28]
10-K	[2017-08-11]
10-Q	[2017-04-07]
10-Q	[2017-01-05]
10-Q	[2016-09-29]
10-K	[2016-08-01]
10-Q	[2016-03-30]
10-Q	[2016-01-07]
10-Q	[2015-10-01]
10-K	[2015-07-31]
10-Q	[2015-04-02]
10-Q	[2015-01-09]
10-Q	[2014-10-08]
10-K	[2014-08-01]
10-Q	[2014-03-28]
10-Q	[2014-01-03]
10-Q	[2013-09-26]
10-K	[2013-08-07]
10-Q	[2013-04-04]
10-Q	[2013-01-04]
10-Q	[2012-10-03]
10-K	[2012-08-08]
10-Q	[2012-03-28]
10-Q	[2012-01-05]